Ahn Sejung, Chae Yeon, Yun Taesik, Kim Hakhyun, Kang Byeong-Teck
Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju, South Korea.
Can Vet J. 2025 Jul 1;66(7):755-763. eCollection 2025 Jul.
An 8-year-old neutered male Maltese dog was presented with 6 palpable cutaneous masses on the neck and thorax 1 y after the surgical excision of mast cell tumors (MCT) from the mid-thoracic and right axillary regions. Before chemotherapy, the sum of the masses' diameters was 19.0 cm. F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) revealed hypermetabolic lesions within the skin overlying the ventral thorax, bilateral prescapular lymph nodes, and right axillary lymph node. The dog was diagnosed with MCT recurrence and treated with combination chemotherapy comprising imatinib, vinblastine, and prednisolone. After completion of 2 16-week chemotherapy regimens, the sum of the masses' diameters decreased to 3.6 cm. For assessment of the chemotherapy response and guidance for subsequent therapeutic plans, follow-up FDG-PET/CT was undertaken 25 d after completion of the 2nd chemotherapy regimen. It demonstrated a reduction in FDG uptake in all areas compared with that on the initial scan, except for the middle thoracic mass. After follow-up FDG-PET/CT, a 3rd chemotherapy regimen was implemented, and the dog died 416 d after the initiation of chemotherapy. There are no reports of a combination chemotherapy with imatinib, vinblastine, and prednisolone for treating canine cutaneous MCT. This case highlighted the potential therapeutic use of this combination chemotherapy for recurrent canine MCTs. Furthermore, this report indicates that FDG-PET/CT may be useful for assessing malignancy, evaluating chemotherapy responses, and establishing treatment plans for canine cutaneous MCTs. Key clinical message: Combination chemotherapy of imatinib, vinblastine, and prednisolone is a potential therapeutic regimen for recurrent cutaneous MCTs in dogs. In addition, FDG-PET/CT may be a potentially useful tool for assessing malignancy, evaluating chemotherapy responses, and guiding further therapeutic decisions.
一只8岁已绝育的雄性马尔济斯犬，在中胸部和右腋窝区域的肥大细胞瘤（MCT）手术切除1年后，颈部和胸部出现6个可触及的皮肤肿块。化疗前，肿块直径总和为19.0厘米。氟脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）显示，胸前壁皮肤、双侧肩胛前淋巴结和右腋窝淋巴结内有高代谢病变。该犬被诊断为MCT复发，并接受了包含伊马替尼、长春碱和泼尼松龙的联合化疗。在完成2个16周的化疗方案后，肿块直径总和降至3.6厘米。为评估化疗反应并指导后续治疗方案，在第2个化疗方案完成后25天进行了随访FDG-PET/CT检查。结果显示，与初始扫描相比，除中胸部肿块外，所有区域的FDG摄取均减少。随访FDG-PET/CT后，实施了第3个化疗方案，该犬在化疗开始后416天死亡。目前尚无关于伊马替尼、长春碱和泼尼松龙联合化疗治疗犬皮肤MCT的报道。该病例突出了这种联合化疗对复发性犬MCT的潜在治疗作用。此外，本报告表明，FDG-PET/CT可能有助于评估犬皮肤MCT的恶性程度、评估化疗反应以及制定治疗方案。关键临床信息：伊马替尼、长春碱和泼尼松龙联合化疗是犬复发性皮肤MCT的一种潜在治疗方案。此外，FDG-PET/CT可能是评估恶性程度、评估化疗反应以及指导进一步治疗决策的潜在有用工具。
